View : 35 Download: 0

Postmastectomy radiotherapy in patients with pT1-2N1 breast cancer treated with taxane-based chemotherapy: A retrospective multicenter analysis (KROG 1418)

Title
Postmastectomy radiotherapy in patients with pT1-2N1 breast cancer treated with taxane-based chemotherapy: A retrospective multicenter analysis (KROG 1418)
Authors
Kim Y.-J.Park W.Ha B.Park B.Joo J.Kim T.H.Park I.H.Lee K.S.Lee E.S.Shin K.H.Kim H.Yu J.I.Choi D.H.Huh S.J.Wee C.W.Kim K.Park K.R.Kim Y.B.Ahn S.J.Lee J.H.Kim J.H.Chun M.Lee H.-S.Kim J.S.Cha J.
Ewha Authors
김규보박경란
SCOPUS Author ID
김규보scopus; 박경란scopus
Issue Date
2017
Journal Title
Cancer Research and Treatment
ISSN
1598-2998JCR Link
Citation
Cancer Research and Treatment vol. 49, no. 4, pp. 927 - 936
Keywords
Breast neoplasmsDisease-free survivalRadiotherapyRecurrenceSurvivalTaxane
Publisher
Korean Cancer Association
Indexed
SCIE; SCOPUS; KCI WOS scopus
Document Type
Article
Abstract
Purpose The purpose of this study was to evaluate the impact of postmastectomy radiotherapy (PMRT) on loco-regional recurrence-free survival (LRRFS), disease-free survival (DFS), and overall survival (OS) in pT1-2N1 patients treated with taxane-based chemotherapy. Materials and Methods We retrospectively reviewed the medical data of pathological N1 patients who were treated with modified radical mastectomy and adjuvant taxane-based chemotherapy in 12 hospitals between January 2006 and December 2010. Results We identified 714 consecutive patients. The median follow-up duration was 69 months (range, 1 to 114 months) and the 5-year LRRFS, DFS, and OS rates were 97%, 94%, and 98%, respectively, in patients who received PMRT (PMRT [+]). The corresponding figures were 96%, 90%, and 96%, respectively, in patients who did not receive PMRT (PMRT [-]). PMRT had no significant impact on survival. Upon multivariable analysis, only the histological grade (HG) was statistically significant as a prognostic factor for LRRFS and DFS. In a subgroup analysis of HG 3 patients, PMRT (+) showed better DFS (p=0.081). Conclusion PMRT had no significant impact on LRRFS, DFS, or OS in pT1-2N1 patients treated with taxane- based chemotherapy. PMRT showed a marginal benefit for DFS in HG 3 patients. Randomized studies are needed to confirm the benefit of PMRT in high risk patients, such as those with HG 3. © 2017 by the Korean Cancer Association.
DOI
10.4143/crt.2016.508
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE